Despite potential increases in comorbidities, co-medication, and physical impairment among geriatric psoriasis patients, their experience of psoriasis is much the same as for patients under age 65. In fact, researchers (Acta Derm Venereol. 10:2340) found that an increased frequency of erythrodermic psoriasis was the main difference between the age groups.

Responses to the self-assessment survey sent to all members of the Dutch Psoriasis Association found no difference regarding systemic antipsoriatic treatment (38.3% vs 42.3%) among those age 65 or older compared to those under age 65. Treatment-related side-effects were reported more frequently by patients under age 65.